Idiopathic Pulmonary Fibrosis (IPF) is a relentlessly progressive fibrotic interstitial lung disease (ILD) with an unfavourable prognosis1. The median survival is 3 to 5 years form the time of diagnosis, but two antifibrotic agents, namely Nintedanib and Pirfenidone, have been shown to slow the decline of lung function (without any significant impact on quality-of-life (QoL)) [1,2]. IPF manifests as an unpredictable trajectory, wherein certain individuals undergo prolonged phases of gradual and progressive deterioration, while others are prone to acute exacerbations [1]; consequently, healthcare providers, patients, and caregivers frequently struggle to discern the variable nature of the disease's progression, leading to elevated levels of stress and anxiety [3].
